OUR SCIENTIFIC APPROACH

Landmark Vaccines operates at the intersection of immunology, materials science, and bioengineering, leveraging multiple technology platforms to create vaccines that are optimised for both efficacy and practicality.

1. Sub-Unit Vaccine Platforms

We develop vaccines using recombinant proteins, peptides, and inactivated antigens that have well-established safety profiles. By pairing these with next-generation adjuvants and delivery systems, we enhance immune responses while reducing the reactogenicity commonly associated with traditional injections.
These sub-unit formulations are ideal for infectious diseases where established antigenic targets exist but delivery remains a challenge - such as influenza, COVID-19, hepatitis, and HPV.

2. Nucleic Acid–Based Vaccines

We are advancing DNA and mRNA vaccine candidates using proprietary microneedle and cell-penetrating delivery technologies. These approaches facilitate precise transfection of antigen-encoding sequences directly into target cells in the skin, where dense networks of antigen-presenting cells trigger rapid and durable immune activation.
Unlike traditional injection-based mRNA vaccines, Landmark’s delivery platforms aim to reduce dose requirements, improve tolerability, and eliminate the need for cold-chain distribution.

3. Immune Therapy and Personalised Vaccines

Our immune therapy program applies the same platforms to oncology, autoimmune, and chronic infectious diseases, where modulation of immune pathways is crucial. By enabling localised or systemic immune activation through skin-based delivery, Landmark Vaccines is pioneering new approaches to therapeutic vaccination, including cancer neoantigen vaccines and immune-modulating RNA constructs.